1. **TITLE: Effect modification in network meta-analyses of treatments for relapsing refractory**

2. **multiple myeloma (RRMM): systematic review, meta-analysis, and simulation**

3.

4. **RUNNING HEAD: Effect modification in NMAs for RRMM**

5.

6. Christopher James Rose[1,2,*]; Ingrid Kristine Ohm[1]; Liv Giske[1]; Gunn Eva Næss[1];

7. Atle Fretheim[2]

8.

9. 1. Reviews and Health Technology Assessments, Division for Health Services, Norwegian

10. Institute of Public Health, Oslo, Norway

11. 2. Center for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo,

12. Norway

13. * Corresponding author (cjro@fhi.no)

14.

15. Counts:

16.   Abstract: 250 words   (limit = 250 words)

17.   Main text: 4306 words   (limit = 4000 words)

18.   Number of figures/tables: 6   (limit = 7 figures/tables)

19.   Number of references: 71   (limit = 100 references)

20.

ABSTRACT

Aims Network meta-analysis (NMA) has been used in several systematic reviews on relapsing

refractory multiple myeloma (RRMM). NMAs have been questioned on the basis that effect

modification may invalidate the underpinning assumptions. We aimed to systematically review

and meta-analyze the evidence for effect modification of hazard ratios (HRs) for overall survival

(OS) and progression-free survival (PFS) with respect to refractory status and number of

treatment lines.

Methods We extracted stratified HR estimates from 42 phase 2 and 3 randomized controlled

trials (RCTs). We tested for within-study effect modification and used meta-analyses to estimate

ratios of hazard ratios (RHRs) across trial under assumptions that strongly favor the modification

hypothesis. RHR estimates were used in simulations to estimate how many NMA results would

be expected to differ in the presence versus absence of effect modification.

Results Most (95%) publications could have reported stratified estimates but only 14% (OS) and

43% (PFS) did. Within-study evidence for effect modification is very weak ($p > 0.05$ for 47 of 49

sets of stratified estimates). The largest RHR estimated was 1.31 (95% CI 1.16–1.47), for the

modifying effect of refractory status on HR for PFS. Simulations suggest that, in the worst case,

effect modification would result in 4.48% (95% CI 4.42%–4.53%) of NMA estimates differing

statistically significantly in the presence versus absence of effect modification.

Conclusions Effect modification is essentially undetectable in phase 2 and 3 trials. In the worst

case, it is unlikely to affect more than about 5% of random-effects NMA estimates.

KEYWORDS

relapsing refractory multiple myeloma; RRMM; effect modification; stratification; systematic

review; meta-analysis; network meta-analysis; simulation study

INTRODUCTION

A defining characteristic of relapsing refractory multiple myeloma (RRMM) is that patients either

do not respond, or stop responding — i.e., are refractory — to specific treatments.[1] Refractory

patients must switch to alternative treatments, if available. Multiple treatment options now

exist, and the treatment regimens often comprise multiple drugs in combination. This naturally

leads to questions about treatment superiority. These have been addressed in several systematic

reviews that have used network meta-analysis (NMA).[2,3,4,5,6,7]

If the assumptions underpinning an NMA model are sufficiently satisfied, NMA facilitates meta-

analytical estimation of all pairs of treatment effects, including between treatments that have

not been compared directly in a trial. One of these assumptions is called the transitivity

assumption[8,9,10] which, informally, means that a treatment effect for one comparison can be

calculated by adding or subtracting treatment effects for other comparisons in the network. This

allows treatment effects to be estimated for pairs of treatments that have not been directly

compared by the trials included in the network (i.e., indirect comparisons).

NMAs should assess and report on the likely validity of the transitivity assumption. This requires

comparing distributions of effect modifiers across trials.[8] An effect modifier is a variable that

causes a difference in treatment effect but is not itself a treatment or an outcome.[11,12] In plain

English: effect modification is about stratification — when effect modification occurs, treatment

effect is different for different subgroups of patients. It is important to distinguish between a

variable that is associated with *treatment effect* (a comparison between treatments) and a

variable that is only associated with *outcome* (e.g., overall survival for a particular patient). The

former is an effect modifier, but the latter is a risk factor. Number of lines of treatment (LOT) is

presumably a risk factor for overall survival, if for no other reason than patients who have

received many LOT will be older. However, that does not mean it is also an effect modifier.

Unfortunately, non-statistical articles on NMA often conflate risk factors and effect modifiers

when considering the transitivity assumption. Risk factors are not a concern for NMAs of RCTs

because, in expectation, randomization excludes the possibility that they account for observed

treatment effects. In large part, this is why RCTs are so useful. However, if a *fixed-effects* NMA is

applied to estimates from trials with different distributions of effect modifiers, the transitivity

assumption will be threatened because the estimates have different interpretations, and with it,

the validity of the NMA. That said, the nature and extent to which an NMA may be invalidated by

effect modification depends on the magnitudes and directions of the modifications. If

modification is small compared to the precisions of the trial estimates, NMA estimates may still

be consistent with the true treatment effects (e.g., confidence intervals may contain the target

parameter values). *Random-effects* NMAs are designed specifically to address heterogeneity in

trial-level treatment effects.

The use of NMA in RRMM has been criticized[13] on the basis that variables such as refractory

status and LOT are effect modifiers, with the implication that NMAs that do not account for effect

modification may be untrustworthy. The present article was motivated by an ongoing health

technology assessment (HTA) we are conducting on treatments for RRMM that was

commissioned via Norway's National System for Managed Introduction of New Health

Technologies within the Specialist Health Service ("Nye Metoder").[14] One of our clinical advisors

highlighted concerns about effect modification with respect to refractory status and LOT. While

these concerns have been raised in previous work,[13] we could not find definitive quantitative

research on effect modification in RRMM that could inform our HTA. We therefore performed a

systematic review and meta-analysis of stratified estimates reported by the trials included in our

HTA. We then used the meta-analysis results in a simulation study to assess the degree to which

NMA estimates are likely to be affected by effect modification.

METHODS

This meta-analysis was not prespecified or registered because it was performed in response to

comments on an ongoing HTA. Further methodological details and completed PRISMA

checklists[15] are available in Supplementary Materials.

Literature search strategy

The search was first performed in February 2020 and was regularly updated until January 2022

(ongoing trials until June 2021). We limited the search to RCTs, used the search term Multiple

Myeloma, and used MeSH-terms and text words. Halfway through we limited the search to

include the terms Relapse or Refractory. The full strategy is presented in Supplementary

Materials. We also contacted project stakeholders, including industry, to solicit suggestions for

potentially relevant publications. We did not systematically search beyond this work to support

our HTA because we are primarily interested in effect modification within the trials included in

our HTA. Via manual searching we found nine articles reporting stratified estimates for the

included trials[16,17,18,19,20,21,22,23,24] but used stratified estimates from the main trial publications,

because they are more likely to have been prespecified.

Inclusion and exclusion criteria

From the identified publications, we included those that provide estimates of hazard ratios (HRs)

for OS or PFS that could be included in NMAs (i.e., those that report point estimates and a

statement of precision such as a confidence interval or *p*-value). We excluded trials comparing

doses or schedules of the same treatment.

We excluded publications from meta-analysis if they did not report stratified estimates of HR for

all strata for at least one of two potential effect-modifiers (e.g., we would have excluded a study

if it did report an estimate for lenalidomide-refractory patients but did not report an estimate for

patients not refractory to lenalidomide). We excluded publications that did not report numerical

statements of uncertainty on stratified estimates (e.g., we excluded one study that reported

point estimates numerically but only provided a graphical presentation of the confidence

intervals).

Data extraction

CJR extracted data from trial reports and supplementary materials. Extracted data were checked

independently by IKO. Disagreements were resolved via discussion. We extracted estimates of

HR for OS and PFS, stratified by LOT and refractory status or previous use of immunomodulatory

drugs (IMiDs; see below), where available. For LOT, we extracted data using the categorizations

used by the publications (e.g., Attal 2019 used 2–3 vs >3 LOT, while Dimopoulos 2016 used 1 vs

2 vs 3 vs >3 LOT). For refractory status we preferentially extracted estimates stratified by

refractory status with respect to lenalidomide (Revlimid), which was identified as being of

particular concern by our clinical advisor (i.e., if stratified estimates were available for

lenalidomide-refractory patients and patients not refractory to lenalidomide, we extracted these

estimates). If this information was not reported, we extracted estimates for refractory status with

respect to other named IMiDs such as thalidomide (of which lenalidomide is an analog). If this

information was not reported, we extracted estimates for refractory status with respect to IMiDs

in general. If this information was not available, we extracted estimates stratified by previous use

of lenalidomide or other IMiDs, on the assumption that previously IMiD use is a reasonable proxy

for being refractory to an IMiD. For the same reason, we did not extract estimates stratified by

LOT and refractory status simultaneously (e.g., comparing OS in lenalidomide-refractory patients

with one LOT). In summary, we used a pragmatic and inclusive definition of refractory status

rather than a strict definition that would have yielded very little evidence on effect modification.

For brevity we call this concept "refractory status" in the remainder of the article. However,

readers are reminded that the concept is broader than this name implies (the statistical analysis

section describes how we address the issue statistically).

Statistical analyses

We first performed pairwise random-effects meta-analyses of stratified HRs, grouped by trial, for

refractory status and LOT. This facilitates testing for evidence of effect modification within each

trial. Because these analyses yielded very weak evidence for effect modification, but there

nevertheless seems to be strong opinions that effect modification does occur and is a problem

for NMAs for RRMM, we then performed pairwise random-effects meta-analyses of ratios of

hazard ratios (RHRs; described below) for refractory status and LOT. This facilitates estimation of

relative magnitudes of effect modification and allows us to test for effect modification by pooling

all evidence of effect modification across trial and treatment comparison.

RHRs were computed for each trial as follows (a formal definition is provided in Supplementary

Materials). First, the trial's strata were sorted to ensure that the order of strata have similar

interpretations across trials and are therefore amenable to meta-analysis. For example, LOT

strata were sorted from fewest to most LOT, and previous lenalidomide use was nominated as

the first (i.e., reference) level of the refractory status factor variable. Then, we computed the

ratio between the HR for each stratum and the HR for its preceding stratum (except for the first

stratum, which is the reference). Finally, we "inverted" any of these ratios with a point estimate

less than one to ensure that point estimates for all RHRs are greater than or equal to one. This

inversion step is necessary to prevent ratios less than one from cancelling ratios greater than one

in the meta-analyses and thereby obscuring any evidence of effect modification (see below).

Standard errors on RHRs were computed as described in Supplementary Materials. We excluded

reference strata from meta-analysis because, as references, they are not defined with respect to

another stratum.

The RHR scale removes heterogeneity in direction of treatment effect within and between trials

and facilitates meta-analysis across all trials such as to make evidence of effect modification

statistically detectable; it therefore strongly favors the effect modification hypothesis. A RHR tells

us how many times larger a stratified estimate is compared to the estimate for its preceding

stratum (or vice versa). If the meta-analytical estimate of mean RHR differs statistically from

RHR = 1, then we can reject the null hypothesis of no effect modification.

All meta-analyses were performed on the logarithmic scale. We used random-effects models

throughout because there are important differences in the definitions of refractory status and

LOT used across the trials which would be expected to manifest as heterogeneity, and which

must be accounted for statistically. We present results using forest plots, sub-grouped by

publication, to report estimates of mean HRs or mean RHRs, 95% confidence intervals, and I^2 and

p-values throughout. We used the conventional $p < 0.05$ criterion for statistical significance.

Statistical analyses were performed using Stata 16 (StataCorp LLC, College Station, Texas, USA).

Data and code are freely available (see the Data and Software Availability section).

Simulation studies

To help understand the degree to which effect modification may affect NMA results, we

performed two simulation studies (plus various sensitivity analyses; see Discussion). The purpose

of the simulations was to estimate the percentage of NMA estimates that would be expected to

be statistically significantly different under effect modification compared to no effect

modification, due to refractory status and LOT. Figure 1 shows a cartoon that illustrates the

design of these studies.

Insert Figure 1 about here

Each simulation used 1000 pairs of synthetic networks of evidence, generated to be similar in

distribution to the real network for PFS (the outcome for which RHRs were estimated to be

largest; see Results). Networks within a pair were identical except that one network was

subjected to simulated effect modification and the other was not, such that any differences in

NMA estimates between the two networks could only be attributed to the impact of effect

modification. All networks had the same topology as the network for PFS. Simulated effect sizes

(log HRs) and their standard errors were drawn from distributions that matched those for the PFS

data.

We used estimates of RHR for PFS because they were larger than for OS (i.e., we assumed worst-

case scenarios), simulating effect modification by sampling from normal distributions

parameterized by mean RHRs and their standard errors to account for uncertainty on the

estimates of RHR. We fitted random-effects component-NMA models[25] to each pair of simulated

networks and tested null hypotheses of no differences between corresponding estimates. Testing

was performed using two-sided *Z*-tests using the estimated log HRs and their standard errors.

Corresponding estimates were deemed to differ if $p < 0.05$. We summarized the results of each

simulation as the percentage of estimates expected to be statistically significantly different under

effect modification compared to no effect modification. Simulations were performed using R

version 3.5.2[26] with component NMAs performed using the netmeta[27] package (version 1.3-0).

Further details are available in Supplementary Methods.

RESULTS

Systematic literature searching identified 810 references, of which 40 publications contributed

stratified estimates (see Supplementary Materials). Table 1 summarizes the included

publications. It shows which trials could have reported stratified estimates (because they

included patients that differ with respect to refractory status or LOT) and did so; trials and

publications that could have reported stratified estimates but chose not to; and trials that could

not report stratified estimates.

Insert Table 1 about here

Effect modification of HR for progression-free survival

Almost all trials could have reported stratified estimates, but only 17 (40%) publications,

representing 8364 patients, did report estimates stratified by refractory status (Table 1).

Similarly, 18 (43%) publications, representing 7,503 patients, did report estimates stratified by

LOT (Table 1). Within-trial evidence for effect modification of HR for PFS by refractory status and

LOT is weak (Figure 2 and Figure 3). Only one test for equality of stratified HRs was statistically

significant with respect to refractory status ($p < 0.01$ for the comparison Kd vs Vd[28]) and another

with respect to LOT ($p = 0.01$ for the comparison DVd vs Vd[29]).

Insert Figure 2 about here

Insert Figure 3 about here

242   Mean RHR was estimated to be 1.31 (95% CI 1.16 to 1.47; $p < 0.005$; $I^2 = 0\%$) for refractory status

243   and 1.19 (95% CI 1.09 to 1.29; $p < 0.01$; $I^2 = 0\%$) for LOT (Figure 4). No statistical heterogeneity in

244   RHR was observed.

Insert Figure 4 about here

Effect modification of HR for overall survival

Almost all trials could have reported stratified estimates for OS. Only 6 publications (14%),

representing 3,471 patients, did report estimates stratified by refractory status (Table 1).

Similarly, only 7 (17%) publications, representing 4,063 patients, did report estimates stratified

by LOT (Table 1). Within-trial evidence for effect modification of HR for OS by refractory status

and LOT is very weak, with no tests for equality of stratified HRs demonstrating statistical

significance (Supplementary Materials).

Mean RHR was estimated to be 1.16 (95% CI 1.01 to 1.32; $p = 0.03$; $I^2 = 0\%$) for refractory status

and 1.09 (95% CI 0.98 to 1.20; $p = 0.12$; $I^2 = 0\%$) for LOT (Supplementary Materials). No statistical

heterogeneity in RHR was observed, suggesting that effect modification may be relatively

consistent across trial and comparison, and that our broad definitions of refractory status and

LOT did not introduce undue heterogeneity.

Simulation study

Table 2 summarizes the results for the simulations. We would expect no more than 0.4% of NMA

estimates for PFS to differ if trial estimates are, versus are not, subject to effect modification by

refractory status. I.e., among the 595 possible comparisons of the 35 treatments in the included

trials on PFS, we would expect no more than about 2–3 comparisons to differ statistically

significantly due to effect modification. We would expect no more than 5% of NMA estimates for

PFS to differ if trial estimates are, versus are not, subject to effect modification by LOT. I.e.,

among the 595 possible comparisons, no more than about 30 comparisons would be expected

to differ statistically significantly due to effect modification.

Insert Table 2 about here

DISCUSSION

We have systematically reviewed and meta-analyzed the evidence for effect modification of HR

for OS and PFS stratified by refractory status and LOT. Within-trial evidence for effect

modification of HR for OS and PFS by refractory status and LOT is weak, with only 2 of 49 tests of

heterogeneity demonstrating statistical significance (i.e., almost exactly the number of type I

errors expected at the 95% significance level under the null hypothesis of no effect modification).

Of the meta-analyses of cross-trial effect modification, the largest (i.e., worst-case) mean RHR

estimated was 1.31 (95% CI 1.16 to 1.47) for HR for PFS with respect to refractory status.

We then used worst-case estimates of RHR in simulations to estimate percentages of NMA

estimates that may be affected by effect modification. For refractory status, the simulations

suggest that even if effect modification is as large as the worst-case estimate, substantially fewer

than 1% of NMA estimates are likely to be statistically different than they would be if effect

modification does not occur. For LOT, the simulations suggest that fewer than 5% of NMA

estimates are likely to be statistically different in the presence of effect modification and

heterogeneity. This is substantially higher than for refractory status, but putting this result in

perspective, 5% is the same as our typical tolerance for type I errors given by the conventional

significance level of 95%.

Absence of evidence is not evidence of absence, and we may simply not have sufficient data to

detect the impact of effect modification. Still, if effect modification does occur, we would expect

to see consistent patterns which support effect modification, which we do not. In some cases,

estimates increase with refractory status or LOT, in others it is opposite, but in most cases the

estimates are practically the same.

Cope et al. qualitatively assessed 12 NMAs or unanchored indirect comparisons and, based on

expert opinions on variables that may be effect modifiers, concluded that the NMA estimates

may have been compromised by differences in distributions of effect modifiers.[13] We are aware

of one other attempt at quantifying effect modification through meta-analysis of results from

subgroups, e.g., patients with one previous LOT vs. 2 or more previous LOT.[6] In this NMA, which

was limited to comparing different immunomodulatory-containing regimens for RRMM,

Dimopoulos et al. reported that their subgroup analyses yielded results consistent with their

main findings (i.e., no apparent effect modification).

Strengths and limitations

To our knowledge, this is the first systematic review, meta-analysis, and simulation study of effect

modification in RRMM. However, it was not prespecified. While we were able to obtain stratified

estimates from up to 18 (43%) of the included publications, most publications did not report

stratified estimates. Because we did not perform a separate literature search, it is possible that

we do not have all the available data on effect modification. However, it would be unreasonable

to expect the smaller trials to report stratified estimates, as they would likely be so imprecise as

to be uninformative. Further, stratified estimates were published for about half as many analyses

of OS compared to PFS, despite there being about the same number of publications providing

estimates of HR for the two outcomes. Because stratified estimates are not reported in the main

trial reports for so many comparisons, it is possible that effect modification is larger than we

estimate, particularly for OS.

While we systematically reviewed evidence of effect modification with respect to refractory

status and number of lines of treatment, we did not systematically review other variables that

also may be effect modifiers. However, we did look at all stratified estimates when extracting

data and did not notice any variables that appeared to consistently demonstrate convincing

evidence of effect modification.

Because there was heterogeneity in trial reporting, we were not able to use definitions of

refractory status and number of lines of treatment that measured exactly what we were

interested in, because doing so would have resulted in almost no synthesizable evidence. We

therefore used pragmatic and inclusive definitions, particularly for refractory status (see

Methods). We would have expected this to introduce heterogeneity, but this was not statistically

observable in the meta-analyses of RHR (I^2 = 0% in all analyses).

Because the within-trial evidence of effect modification is so weak, but there are nevertheless

concerns in the RRMM research community about effect modification and NMA, we constructed

RHR and designed the simulations to strongly favor the effect modification hypothesis. This likely

resulted in exaggerated conclusions about whether effect modification occurs and the extent to

which it is problematic.

Quantities such as ratios of hazard ratios, as used in meta-research,[30] are likely challenging to

interpret, and we suspect that few will have an intuitive understanding of what constitutes a

"large" or "important" RHR with respect to effect modification in RRMM. A major strength of this

work is that having estimated RHRs, we then used simulations to investigate how many NMA

estimates would be expected to be statistically significantly different under the estimated degree

of effect modification. We hope this helps readers understand the likely impact of any effect

modification on NMA estimates. However, we remind readers that we used random-effects

NMAs,[31] which are designed to account for heterogeneity in trial estimates. Our results do not

necessarily translate to fixed-effects NMAs, as used in some systematic reviews on treatments

for RRMM.[4,2] It is important to note that fixed- and random-effects NMAs make fundamentally

different assumptions about transitivity. Fixed-effects NMAs assume that "trial-level" treatment

effects can be added and subtracted to make indirect estimates. Random-effects NMAs assume

that *average* treatment effects can be added and subtracted. Use of average treatment effects

explicitly accounts for differences between trials, including different distributions of effect

modifiers.

Finally, we also performed sensitivity analyses to investigate the implications of the assumptions

we made in the simulations. For example, because RHR discards direction of modification, we

assumed that direction of modification is consistent within treatment comparison but may vary

between comparisons. This may not be true, so we performed a sensitivity analysis in which

direction is assumed consistent within and between comparisons. The result of this analysis

suggests that about half as many estimates would differ statistically compared to the main

analysis (i.e., that the main result reflects the worst-case).

Implications for research

Understandably, the transitivity assumption underpinning NMA is often highly simplified in

articles aimed at non-statisticians. For example, articles tend to use arguments about "similarity"

of patients.[8] Given this oversimplification, it is unsurprising there are concerns about using NMA

in RRMM and other areas. The transitivity assumption does not concern patient similarity, nor

whether treatment effect *estimates* can be added or subtracted, it concerns whether target

parameters can be linearly combined. Patient similarity is a good place to start thinking about

NMAs, but a terrible place to stop. Modern statistical methods should be communicated more

carefully and received more studiously.

Understanding effect modification is important for making decisions based on individual trials,

and for assessing the assumptions and validity of NMAs. We therefore suggest that RRMM

trialists develop and adopt standardized definitions of potential effect modifiers that, where

possible, should be used to report stratified analyses in future trials. In addition to improving

transparency and improving consistency of reporting of effect estimates for patient subgroups,

standardization would facilitate more specific meta-analytical study of effect modification by

reducing methodological heterogeneity. Further, we suggest that stratified analyses be reported

for all patient-important outcomes, particularly OS, which has been dramatically underreported

compared to PFS.

The strength of concerns that effect modification, as it may occur in RRMM, may invalidate NMAs

appears to be inconsistent with the available evidence. This suggests that NMA can probably be

relied upon to estimate direct and indirect treatment effects, subject to some important caveats.

First, evidence on effect modification is limited to at most ~40% of comparisons, so it is possible

that modification is more severe in the remaining ~60% of comparisons. That said, it would be

concerning if large modification occurs but has been systematically unreported in the majority of

phase 2 and 3 trials. Second, more evidence on modification is available for PFS than OS, so it is

possible that HR for OS is subject to greater modification than the available evidence suggests.

This may be because the PFS endpoint is typically reached earlier than that for OS. However,

again, it would be concerning if large modification was not being reported for what is arguably

the most important outcome of cancer trials. Third, we are not suggesting that a particular NMA

estimate can be applied to patients who are refractory to one or both treatments involved in a

given comparison: such estimates would be subject to an obvious, if somewhat absurd, form of

effect modification. A method for ranking treatments for patients who are refractory to specific

treatments or components is presented in the Supplementary Appendix. Fourth, and crucially,

our simulations estimated random-effects (cf. fixed-effects). Random-effects models account for

heterogeneity in effect estimates due not just to sampling error, but also other factors, including

effect modification. Our findings are unlikely to generalize to fixed-effects NMAs. Finally, NMA

should be able to be used to make indirect estimates if effect modification is negligible for all

direct comparisons and there is no good reason to believe that non-negligible modification would

occur for treatment comparisons that have not been made directly. However, it would be

preferable to have direct evidence.

Summary and conclusions

There is very weak within-trial evidence for effect modification with respect to refractory status

and number of previous lines of treatment. It is plausible that effect modification does not occur

with respect to these variables or is so small as to be statistically undetectable, even in phase 3

trials. If this is true, then differences in the distributions of these variables across trials are

unlikely to be a problem in NMAs. We were only able to detect effect modification by estimating

ratios of hazard ratios (RHRs) across trials under assumptions that strongly favor the modification

hypothesis. These assumptions may not hold, so our estimates of the magnitude of effect

modification may be exaggerated, as may our estimates of the percentages of NMA estimates

that would be expected to be affected.

Adequately performed random-effects NMAs can probably be relied upon to provide direct and

indirect estimates of mean HRs for OS and PFS, subject to the caveats discussed above.

418
419

AUTHOR CONTRIBUTIONS

Study conception and design: CJR

Acquisition, analysis, or interpretation of data: CJR, IKO, LG, GEN, AF

Drafting the manuscript: CJR, IKO, GEN, AF

Critical revision of the manuscript for important intellectual content: IKO, LG, GEN, AF

Statistical analysis: CJR

Supervision: AF

All authors approved the published version and agreed to be accountable for all aspects of the

work.

DATA AND SOFTWARE AVAILABILITY

Data and software are publicly available at: https://github.com/multinormal/fhi.rrmm-em.2022

The specific version used to generate the results presented herein is archived at Zenodo:

https://doi.org/10.5281/zenodo.6545584

DISCLOSURE OF CONFLICTS OF INTEREST AND FUNDING

None of the authors have any competing interests with respect to this work.

The authors conducted this research under the employ of the Norwegian Institute of Public

Health (Folkehelseinstituttet). The work was funded via Norway's National System for Managed

Introduction of New Health Technologies within the Specialist Health Service (Nye Metoder). The

funder had no role in the conduct of this work.

SUPPLEMENTARY MATERIAL

The following supplementary material accompanies this manuscript:

1. Supplementary Materials.docx

REFERENCES

1.   van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. *The Lancet*.

445   2021;397(10272):410-427. doi:10.1016/S0140-6736(21)00135-5

446   2.   van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P.

447   Systematic literature review and network meta-analysis of treatment outcomes in

448   relapsed and/or refractory multiple myeloma. *Journal of Clinical Oncology*.

449   2017;35(12):1312-1319.

450   3.   Botta C, Ciliberto D, Rossi M, et al. Network meta-analysis of randomized trials in multiple

451   myeloma: efficacy and safety in relapsed/refractory patients. *Blood Advances*.

452   2017;1(7):455-466.

453   4.   Luo XW, Du XQ, Li JL, Liu XP, Meng XY. Treatment options for refractory/relapsed multiple

454   myeloma: an updated evidence synthesis by network meta-analysis. *Cancer Management*

455   *and Research*. 2018;10:2817.

456   5.   Maiese EM, Ainsworth C, le Moine JG, Ahdesmäki O, Bell J, Hawe E. Comparative efficacy

457   of treatments for previously treated multiple myeloma: a systematic literature review and

458   network meta-analysis. *Clinical Therapeutics*. 2018;40(3):480-494.

459   6.   Dimopoulos MA, Kaufman JL, White D, et al. A comparison of the efficacy of

460   immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a

461   network meta-analysis. *Clinical Lymphoma Myeloma and Leukemia*. 2018;18(3):163-173.

462   7.   Weisel K, Sonneveld P, Spencer A, et al. A comparison of the efficacy of

463   immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network

464   meta-analysis. *Leukemia & Lymphoma*. 2019;60(1):151-162.

8.   Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of

systematic reviews incorporating network meta-analyses of health care interventions:

checklist and explanations. *Ann Intern Med*. 2015;162(11):777-784.

9.   Bagg MK, Salanti G, McAuley JH. Comparing interventions with network meta-analysis.

Journal of Physiotherapy. 2018;64(2):128-132.

10. Dias S, Caldwell DM. Network meta-analysis explained. *Archives of Disease in Childhood -*

Fetal and Neonatal Edition. 2019;104:F8-F12.

11. van der Weele TJ. On the distinction between interaction and effect modification.

Epidemiology. 2009;20(6):863-871.

12. Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect

modification and interaction. *Int J Epidemiol*. 2012;41(2):514-520.

13. Cope S, Clemens A, Hammes F, Noack H, Jansen JP. Critical appraisal of network meta-

analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation

stroke prevention trials. *Value in Health*. 2015;18(2):234-249.

14. Desser A, Fretheim A, Ohm IK, et al. *Treatments for Relapsing, Refractory Multiple*

Myeloma: A Health Technology Assessment — Project Description.; 2021.

15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated

guideline for reporting systematic reviews. *International Journal of Surgery*.

2021;88:105906.

16. San Miguel JF, Weisel KC, Song KW, et al. Impact of prior treatment and depth of response

on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-

dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple

myeloma. *Haematologica*. 2015;100(10):1334.

17.   Richardson PG, Hungria VTM, Yoon SS, et al. Panobinostat plus bortezomib and

dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.

Blood. 2016;127(6):713-721.

18.   Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib–lenalidomide–dexamethasone vs

lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment. *Blood*

Cancer Journal. 2017;7(4):e554–e554.

19.   Mateos MV, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety

of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone

in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Haematologica. 2017;102(10):1767.

20.   Moreau P, Joshua D, Chng WJ, et al. Impact of prior treatment on patients with relapsed

multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and

dexamethasone in the phase 3 ENDEAVOR study. *Leukemia*. 2017;31(1):115-122.

21.   Bringhen S, Pour L, Vorobyev V, et al. Isatuximab plus pomalidomide and dexamethasone

in patients with relapsed/refractory multiple myeloma according to prior lines of

treatment and refractory status: ICARIA-MM subgroup analysis. *Leukemia Research*.

2021;104:106576.

22.   Dimopoulos M, Weisel K, Moreau P, et al. Pomalidomide, bortezomib, and dexamethasone

for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by

prior treatment at first relapse. *Leukemia*. 2021;35(6):1722-1731.

23.   Mateos M v, Gavriatopoulou M, Facon T, et al. Effect of prior treatments on selinexor,

bortezomib, and dexamethasone in previously treated multiple myeloma. *Journal of*

Hematology & Oncology. 2021;14(1):1-5.

24.   Quach H, Nooka A, Samoylova O, et al. Carfilzomib, dexamethasone and daratumumab in

relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior

lines of therapy. *British Journal of Haematology*. 2021;194(4):784-788.

25.   Rücker G, Petropoulou M, Schwarzer G. Network meta-analysis of multicomponent

interventions. *Biometrical Journal*. 2020;62(3):808-821. doi:10.1002/bimj.201800167

26.   R Core Team. *R: A Language and Environment for Statistical Computing*.; 2018.

https://www.R-project.org/

27.   Rücker G, Krahn U, König J, Efthimiou O, Schwarzer G. *Netmeta: Network Meta-Analysis*

Using Frequentist Methods.; 2021. https://CRAN.R-project.org/package=netmeta

28.   Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus

bortezomib and dexamethasone for patients with relapsed or refractory multiple

myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *The Lancet*

Oncology. 2016;17(1):27-38.

29.   Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and

dexamethasone versus bortezomib and dexamethasone in patients with previously

treated multiple myeloma: three-year follow-up of CASTOR. *Clinical Lymphoma Myeloma*

and Leukemia. 2020;20(8):509-518.

30.   Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of

methodological quality associated with estimates of treatment effects in controlled trials.

JAMA. 1995;273(5):408-412.

31.   Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment

comparisons. *Statistics in Medicine*. 2004;23(20):3105-3124.

32.   Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose

dexamethasone versus pomalidomide and low-dose dexamethasone in patients with

relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre,

open-label, phase 3 study. *The Lancet*. 2019;394(10214):2096-2107.

33.   Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and

dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX,

a randomized, open-label, phase 3 study. *Leukemia*. 2020;34(7):1875-1884.

34.   Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed

or refractory multiple myeloma. *New England Journal of Medicine*. 2007;357(21):2123-

2132.

35.   Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with

bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre,

randomised, double-blind study. *The Lancet Oncology*. 2013;14(11):1129-1140.

36.   Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and

dexamethasone for multiple myeloma. *New England Journal of Medicine*.

2018;379(19):1811-1822.

37.   Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone

550   in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study.

551   *Blood Cancer Journal*. 2020;10(9):1-10.

552   38.   Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and

553   dexamethasone versus pomalidomide and dexamethasone alone in previously treated

554   multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *The Lancet*

555   *Oncology*. 2021;22(6):801-812.

556   39.   Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with

557   dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood*.

558   2021;137(9):1154-1165.

559   40.   Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of

560   bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-

561   dexamethasone in patients with multiple myeloma progressing or relapsing after

562   autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the

563   Chronic Leukemia Working Party of the European Group for Blood and Marrow

564   Transplantation. *Journal of Clinical Oncology*. 2012;30(20):2475-2482.

565   41.   Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and

566   dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with

567   multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. *The Lancet*.

568   2020;396(10262):1563-1573.

569   42.   Hájek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low-

570   dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple

571   myeloma (FOCUS). *Leukemia*. 2017;31(1):107-114.

572   43.   Hou J, Jin J, Xu Y, et al. Randomized, double-blind, placebo-controlled phase III study of

573   ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple

574   myeloma: China Continuation study. *Journal of Hematology & Oncology*. 2017;10(1):1-13.

575   44.   Iida S, Wakabayashi M, Tsukasaki K, et al. Bortezomib plus dexamethasone vs thalidomide

576   plus dexamethasone for relapsed or refractory multiple myeloma. *Cancer Science*.

577   2018;109(5):1552-1561.

578   45.   Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus

579   bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

580   *Blood*. 2016;127(23):2833-2840.

581   46.   Kropff M, Vogel M, Bisping G, et al. Bortezomib and low-dose dexamethasone with or

582   without continuous low-dose oral cyclophosphamide for primary refractory or relapsed

583   multiple myeloma: a randomized phase III study. *Annals of Hematology*.

584   2017;96(11):1857-1866.

585   47.   Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with

586   bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

587   (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. *The Lancet Oncology*.

588   2020;21(12):1630-1642.

589   48.   Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory

590   multiple myeloma. *New England Journal of Medicine*. 2015;373(7):621-631.

591   49.   Lu J, Fu W, Li W, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib

592   and dexamethasone in chinese patients with relapsed or refractory multiple myeloma:

593   Phase 3 LEPUS (MMY3009) study. *Clinical Lymphoma Myeloma and Leukemia*.

594   2021;21(9):e699–e709.

595   50.   Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and

596   dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-

597   183): a randomised, open-label, phase 3 trial. *The Lancet Haematology*. 2019;6(9):e459–

598   e469.

599   51.   Montefusco V, Corso A, Galli M, et al. Bortezomib, cyclophosphamide, dexamethasone

600   versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at

601   first relapse. *British Journal of Haematology*. 2020;188(6):907-917.

602   52.   Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for

603   multiple myeloma. *New England Journal of Medicine*. 2016;374(17):1621-1634.

604   53.   Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone

605   in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3

606   trial. *The Lancet*. 2021;397(10292):2361-2371.

607   54.   Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated

608   liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or

609   refractory multiple myeloma: combination therapy improves time to progression. *Journal

610   of Clinical Oncology*. 2007;25(25):3892-3901.

611   55.   Orlowski RZ, Gercheva L, Williams C, et al. A phase 2, randomized, double-blind, placebo-

612   controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in

613   patients with relapsed or refractory multiple myeloma. *American Journal of Hematology*.

614   2015;90(1):42-49.

615   56.   Orlowski RZ, Nagler A, Sonneveld P, et al. Final overall survival results of a randomized trial

616   comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in

617   patients with relapsed or refractory multiple myeloma. *Cancer*. 2016;122(13):2050-2056.

618   57.   Orlowski RZ, Moreau P, Niesvizky R, et al. Carfilzomib-dexamethasone versus bortezomib-

619   dexamethasone in relapsed or refractory multiple myeloma: updated overall survival,

620   safety, and subgroups. *Clinical Lymphoma Myeloma and Leukemia*. 2019;19(8):522-530.

621   58.   Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and

622   dexamethasone for multiple myeloma. *New England Journal of Medicine*.

623   2016;375(8):754-766.

624   59.   Raje NS, Moreau P, Terpos E, et al. Phase 2 study of tabalumab, a human anti-B-cell

625   activating factor antibody, with bortezomib and dexamethasone in patients with

626   previously treated multiple myeloma. *British Journal of Haematology*. 2017;176(5):783-

627   795.

628   60.   Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in

629   relapsed multiple myeloma: final time-to-event results of the APEX trial. *Blood*.

630   2007;110(10):3557-3560.

631   61.   Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose

632   dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2

633   study. *Blood*. 2014;123(12):1826-1832.

634   62.   Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone

635   for patients with relapsed or refractory multiple myeloma previously treated with

636   lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *The Lancet Oncology*.

637   2019;20(6):781-794.

638   63.   Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the

639   TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in

640   patients with relapsed or refractory multiple myeloma. *Journal of Clinical Oncology*.

641   2021;39(22):2430-2442.

642   64.   San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone

643   versus high-dose dexamethasone alone for patients with relapsed and refractory multiple

644   myeloma (MM-003): a randomised, open-label, phase 3 trial. *The lancet oncology*.

645   2013;14(11):1055-1066.

646   65.   San-Miguel JF, Hungria VTM, Yoon SS, et al. Panobinostat plus bortezomib and

647   dexamethasone versus placebo plus bortezomib and dexamethasone in patients with

648   relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-

649   blind phase 3 trial. *The Lancet Oncology*. 2014;15(11):1195-1206.

650   66.   San-Miguel JF, Hungria VTM, Yoon SS, et al. Overall survival of patients with relapsed

651   multiple myeloma treated with panobinostat or placebo plus bortezomib and

652   dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.

653   *The Lancet Haematology*. 2016;3(11):e506–e515.

67.   Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with

carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory

multiple myeloma. *Journal of Clinical Oncology*. 2018;36(8):728-734.

68.   Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and

dexamethasone for relapsed multiple myeloma. *New England Journal of Medicine*.

2015;372(2):142-152.

69.   Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab

versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple

myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label,

phase 3 study. *The Lancet Oncology*. 2022;23(1):65-76.

70.   Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed

multiple myeloma in North America. *New England Journal of Medicine*.

2007;357(21):2133-2142.

71.   White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a

randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed

or refractory multiple myeloma. *Cancer*. 2013;119(2):339-347.

670
671

672 **TABLES**

673 *Table 1: Overview of included publications*

Publication (Trial)	Comparison[†]	Could report HRs stratified by[*]		Does report HRs stratified by[**]			
		Refractory status[††]	Lines of treatment	Refractory status[††]		Lines of treatment	
				OS	PFS	OS	PFS
Attal 2019 (ICARIA-MM)[32]	IsPd vs Pd	✓	✓		✓		✓
Bahlis 2020 (POLLUX)[33]	DRd vs Rd	✓	✓		✓		✓
Dimopoulos 2007 (MM-010)[34]	Rd vs d	✓	✓				
Dimopoulos 2013 (VANTAGE 088)[35]	VorV vs V	✓	✓		✓		✓
Dimopoulos 2016 (ENDEAVOR)[28]	Kd vs Vd	✓	✓		✓		✓
Dimopoulos 2018 (ELOQUENT-3)[36]	EPd vs Pd	✓	✓				
Dimopoulos 2020 (ELOQUENT-2)[37]	ERd vs Rd	✓	✓		✓		✓
Dimopoulos 2021 (APOLLO)[38]	DPd vs Pd	✓	✓				
Dimopoulos 2021[39]	Is vs Isd		✓				
Garderet 2012 (MMVAR/IFM 2005-04)[40]	VTd vs Td	✓					
Grosicki 2020 (BOSTON)[41]	SeVd vs Vd	✓	✓		✓		✓
Hájek 2017 (FOCUS (PX-171-011))[42]	K vs d	✓	✓				
Hou 2017 (China Cont. Study)[43]	IRd vs Rd	✓	✓	✓	✓	✓	✓
Iida 2018[44]	Vd vs Td		✓				
Jakubowiak 2016[45]	EVd vs Vd	✓	✓		✓		✓
Kropff 2017[46]	Vd vs CyVd	✓	✓				
Kumar 2020 (BELLINI)[47]	VeVd vs Vd	✓	✓	✓	✓	✓	✓
Lonial 2015 (ELOQUENT-2)[48]	Eld vs Ld	✓	✓		✓		
Lu 2021 (LEPUS)[49]	DVd vs Vd	✓	✓		✓		✓
Mateos 2019 (KEYNOTE-183)[50]	PemPd vs Pd	✓	✓				
Mateos 2020 (CASTOR)[29]	DVd vs Vd	✓	✓		✓		✓
Montefusco 2020[51]	CyVd vs CyRd	✓					

Moreau 2016 (TOURMALINE-MM1)[52]	IRd vs Rd	✓	✓				
Moreau 2021 (IKEMA)[53]	IsKd vs Kd	✓	✓				
Orlowski 2007 (DOXIL-MMY-3021)[54]	V vs DoxV	✓	✓		✓		
Orlowski 2015[55]	SV vs V	✓	✓				
Orlowski 2016 (DOXIL-MMY-3021)[56]	V vs DoxV	✓	✓	✓			
Orlowski 2019 (ENDEAVOR)[57]	Kd vs Vd	✓	✓	✓		✓	
Palumbo 2016 (CASTOR)[58]	DVd vs Vd	✓	✓		✓		✓
Raje 2017[59]	TabVd vs Vd	✓	✓				
Richardson 2007 (APEX)[60]	V vs d	✓	✓				
Richardson 2014 (MM-02)[61]	Pd vs P	✓	✓				
Richardson 2019 (OPTIMISMM)[62]	PVd vs Vd	✓	✓		✓		✓
Richardson 2021 (TOURMALINE-MM1)[63]	IRd vs Rd	✓	✓	✓		✓	
San-Miguel 2013 (MM-03)[64]	Pd vs d	✓	✓			✓	✓
San-Miguel 2014 (PANORAMA-1)[65]	FVd vs Vd	✓	✓				✓
San-Miguel 2016 (PANORAMA-1)[66]	FVd vs Vd	✓	✓	✓		✓	
Siegel 2018 (ASPIRE)[67]	KRd vs Rd	✓	✓			✓	
Stewart 2015 (ASPIRE)[68]	KRd vs Rd	✓	✓		✓		
Usmani 2022 (CANDOR)[69]	DKd vs Kd	✓	✓		✓		✓
Weber 2007 (MM-09)[70]	Rd vs d	✓	✓				
White 2013 (AMBER)[71]	BevV vs V	✓	✓				
Publications (%)	**42**	**40 (95%)**	**40 (95%)**	**6 (14%)**	**17 (40%)**	**7 (17%)**	**18 (43%)**

*Trials that include only refractory patients, or patients who received a specific number of previous lines of treatment, cannot report stratified estimates. Determinations were made using tables of baseline characteristics and inclusion criteria.

**Publications that report stratified estimates graphically rather than numerically are classified as not reporting stratified estimates. Publications that report a stratified estimate for only one stratum (e.g., refractory but not also non-refractory) are classified as not reporting stratified estimates as they provide incomplete information. It would not be practical or possible for some trials to report stratified estimates due to very small sample sizes or no or very few events.

†Treatment names are listed in full in Supplementary Materials.

††A broad definition of refractory status or previous treatment use was used (see Methods).

675   *Table 2: Simulation study results: Percentages of NMA estimates for progression free survival*

676   *expected to differ in the presence of effect modification and heterogeneity*

Potential effect modifier	NMA estimates expected to differ (95% CI)
Refractory status[*]	0.35% (0.33%–0.36%)
Lines of Treatment[†]	4.48% (4.42%–4.53%)

[*]A broad definition of refractory status or previous treatment use was used (see Methods).
[†]Results for lines of treatment assume four categories, that effect modification consistently increases or decreases with LOT, and that effect modification compounds over categories (see Methods).

FIGURE LEGENDS

Figure 1: Cartoon of the simulation study

Each panel shows one of the 1000 pairs of simulated networks. Within a pair, the estimates of

one network (the topmost in the cartoon) were only subject to simulated heterogeneity, while

the other was subject to heterogeneity and effect modification. Each network in the cartoon has

5 treatments (A, B, …, E), but the simulations used 35 treatments. The magnitudes of direct

estimates of effect are indicated by the lengths of the links between treatments (heterogeneity

and effect modification affect the magnitudes of the estimates, and in extreme cases, their

directions). Direct estimates that are particularly modified are shown as red links. NMA results

are indicated by the matrices. Diagonal elements are not considered further (shaded) because

there is no treatment effect between one treatment and itself. Lower triangles are not

considered further (shaded) because they are identical to the upper triangles except for direction

(sign). Corresponding estimates within a pair are tested for equality, and those that differ

significantly are counted. Effect modification is quite severe in the first and final simulations

illustrated by the cartoon, with 7 and 8 estimates differing. No estimates are statistically different

in the final simulation. These numbers are merely illustrative. By performing many simulations it

is possible to estimate the proportion of NMA estimates that would expected to be affected by

the degree of effect modification observed in the literature.

Figure 2: Hazard ratios for PFS stratified by refractory status

Statistically significant stratified estimates of HR indicate likely treatment effect in specific patient

subgroups. Effect modification would be demonstrated by unequal stratified HRs within trial.

Only one of the 17 within-trial tests for equality of stratified HRs give statistically significant

results at the 95% significance level. Note the lack of a consistent pattern in the estimates across

trial that would lend face-validity to the effect modification hypothesis.

Figure 3: Hazard ratios for PFS stratified by number of lines of

Statistically significant stratified estimates of HR indicate likely treatment effect in specific patient

subgroups. Effect modification would be demonstrated by unequal stratified HRs within trial.

Only one of the 18 within-trial tests for equality of stratified HRs give statistically significant

results at the 95% significance level. Note the lack of a consistent pattern in the estimates across

trial that would lend face-validity to the effect modification hypothesis.

Figure 4: Estimates of ratios of hazard ratios for

The panels show estimates of ratios of hazard ratios (RHRs) constructed under conditions that

favor the effect modification hypothesis. The top panel shows RHRs for refractory status and the

bottom panel shows RHRs for number of lines of treatment. RHR = 1 corresponds to no effect

modification.

FIGURES

Figure 1: Cartoon of the simulation study

Figure 2: Hazard ratios for PFS stratified by refractory status

Figure 3: Hazard ratios for PFS stratified by number of lines of treatment

Figure 4: Estimates of ratios of hazard ratios for PFS

730